Connected Care and Personalised Treatment

You are invited to our next event. The door of the building will be closed at 6 pm. Please note that there will be a person escorting you up to the floor only until 6:30 pm.

6 pm Refreshments

6:20 pm Meeting starts

Nibbles and softdrinks will be provided by ResMed.

1. “An Industry Perspective on the Growth of Connected Care and its Evolution to Personalised Treatment of Sleep-Disordered Breathing”

by Jeff Armitstead (https://www.linkedin.com/in/jeffarmitstead/), M. Biomed. E., PhD, SMIEEE, Vice President Clinical Science & Innovation, ResMed Ltd., Adjunct Professor, University of Sydney

Modern medical devices for the treatment of　sleep-disordered breathing (CPAP) include sophisticated treatment and monitoring algorithms and cloud connectivity via integrated mobile wireless capability. This enables P4 medicine through personalised treatment algorithms, patient engagement　via smartphone apps and the potential for predictive monitoring of disease state.

Jeff Armitstead received both the MBiomed Eng. and PhD degrees in biomedical engineering from the University of New South Wales, Australia, in 1993 and 2002, respectively. After several years working in academia, as a hospital research engineer and as a consultant he joined ResMed Ltd. in 2003 where he is now Vice President of Clinical Science & Innovation. Here he leads teams that develop innovative solutions for the diagnosis and treatment of medical disorders. He maintains strong contacts with many institutions as an advisor, mentor and guest lecturer including UNSW and the University of Sydney where he holds an Adjunct Professorship. His research interests span sleep and respiratory medicine, algorithms and analytics techniques, innovation models and the burgeoning field of big data in healthcare.

2. “Point of care in vitro diagnostics + m-health”

by Luis Daniel López-Sánchez (https://www.linkedin.com/in/luis-daniel-l%C3%B3pez-s%C3%A1nchez-5b624864/), Senior Data Scientist at GRONADE, Cofounder & Lead Scientist @ Botón Médico

Advancements in antibody engineering, hybridization techniques, microfluidics and nanotechnology have allowed the development of a wide variety of high quality analytical products for in vitro diagnostics (IVD) at the point of care — that is, medical testing at the time and place of patient care. In spite of this, penetration of IVD products in m-health environments remains limited mostly to glucose sensors. In this talk I will review how efforts in this direction combined with smartphones, IoT systems, computer vision and machine learning pave the way for expanding m-health product lines to include IVD devices. The benefits of this integration are manifold, especially in developing countries where access to quality healthcare is hindered by high costs and an insufficient number of professionals. We will focus on the Mexican market by presenting high-level insights on the country’s epidemiological profile.